NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia<
15 Oct 2021

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia

FDA has granted ODD for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia.
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology<
13 Oct 2021

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise
Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting<
11 Oct 2021

Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting

There have been no related serious adverse events, dose limiting toxicities, or grade 3 adverse events observed during the study.
Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS)<
06 Oct 2021

Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS)

This venture debt operation is supported by the European Guarantee Fund (EGF) — part of the €540 billion EU response to the economic impact of COVID-19.
Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival<
30 Sep 2021

Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

This study confirms our previous findings and the clinical utility of MAF Test® as a unique tool for precision medicine in early breast cancer.

Aura Biosciences Expands Executive Leadership Team and Board of Directors<
29 Sep 2021

Aura Biosciences Expands Executive Leadership Team and Board of Directors

Appointment of Chris Primiano, J.D., as Chief Business Officer and the appointment of Antony Mattessich to its Board of Directors.
CorWave Attracts Global Talent, Strengthening Its Management Team in Preparation for Clinical Phase and Industrial Ramp Up<
21 Sep 2021

CorWave Attracts Global Talent, Strengthening Its Management Team in Preparation for Clinical Phase and Industrial Ramp Up

Two seasoned industry experts are joining the company: Paul Cornelison (USA) as Vice President, Regulatory Affairs, Quality Assurance and Clinical Affairs, and Michael Webb (Australia) as Vice President, Manufacturing.
AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.<
15 Sep 2021

AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.

Lars’ experience as a CFO at companies as they move toward commercialization will contribute greatly to AM-Pharma’s strengths and we are excited to welcome him.
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis<
14 Sep 2021

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications.
Ysios Capital achieves Certification under the Diversity VC Standard<
09 Sep 2021

Ysios Capital achieves Certification under the Diversity VC Standard

Ysios Capital is the first specialized venture capital firm in life sciences globally and the first Spanish firm to achieve the Diversity VC Standard.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.